Recently, there has been increasing interest in the development of small, non-peptide inhibitors of the β-amyloid cleaving enzyme 1 (BACE-1, β-secretase) [17,18,19,20,21,22,23,24], following the suggestion that this enzyme may be involved in the pathogenesis of Alzheimer’s Disease (AD) [19,25]. Here, BACE1 is linked to Alzheimer disease.